KDx Diagnostics UroGPO partner to offer URO17 non-invasive urine test for bladder cancer

KDx Diagnostics, a company focused on developing non-invasive cancer tests to improve early detection and therapy decisions in cancer, and UroGPO, a specialty networks company, announced the partnership to provide the URO17 test (Research Use Only in the US) for the detection of bladder cancer. URO17 is a non-invasive urine test with high sensitivity and negative predicted value (NPV) that can be used to determine the status of active bladder cancer and to improve patient diagnosis. This is also likely to improve the treatment path as URO17 is also now available as a Laboratory Developed Test (LDT) in the United States. UroGPO will offer reagents and information for the URO17 test to the members of their Group Purchasing Organization. With over 85,000 new cases of bladder cancer in the United States every year the most common symptom of bladder cancer is haematuria, or blood in the urine, and patients with haematuria need to be subjected to invasive cystoscopic procedures even though a large majority of patients with micro-hematuria will not have bladder cancer. The URO17 test, and its high sensitivity and NPV for bladder cancer, will assist in ruling these patients out for unnecessary cystoscopy and its invasive procedure and in turn reduce the work-up. "We are very excited to partner with UroGPO, the premier urology network and group purchasing organization in the US, to make our URO17 test and information available to their network of clinical laboratories. Through UroGPO, the urology laboratories will have direct access to ordering with a special in-network pricing which will facilitate the availability of URO17 to the urologists," says Sholeh Jahanfard, president of KDx Diagnostics Inc. "UroGPO is happy to present this new partnership to our membership. The URO17 test adds efficiency and precision to the care of patients with bladder cancer. KDx has taken steps to remove barriers of access for both physicians and patients which will ultimately benefit patient outcomes, improve quality of life, and even mortality," says Palmer DePetro, Sr. Director, Contracting at Specialty Networks. Founded in 2017, KDx is focused on developing non-invasive cancer tests to improve early detection and therapy decisions in cancer. UroGPO, a specialty networks company, is the first and largest urology-specific Group Purchasing Organization (GPO) in the United States, comprised of more than 700 of the largest, most progressive independent urology practices in the country. Specialty Networks brings together the functional expertise of UroGPO, GastroGPO, PPS Analytics, and SN Research to deliver innovative and meaningful solutions for independent specialty providers.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!